Skip to main content
Erschienen in: Inflammation Research 8/2023

14.08.2023 | Original Research Paper

A novel CD8+ T cell-related gene signature for predicting the prognosis and immunotherapy efficacy in bladder cancer

verfasst von: Fei Lin, Zhi-Bin Ke, Yu-Ting Xue, Jia-Yin Chen, Hai Cai, Yun-Zhi Lin, Xiao-Dong Li, Yong Wei, Xue-Yi Xue, Ning Xu

Erschienen in: Inflammation Research | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

To identify CD8+ T cell-related molecular clusters and establish a novel gene signature for predicting the prognosis and efficacy of immunotherapy in bladder cancer (BCa).

Methods

Transcriptome and clinical data of BCa samples were obtained from the Cancer Genome Atlas (TCGA) and GEO databases. The CD8+ T cell-related genes were screened through the CIBERSORT algorithm and correlation analysis. Consensus clustering analysis was utilized to identified CD8+ T cell-related molecular clusters. A novel CD8+ T cell-related prognostic model was developed using univariate Cox regression analysis and Lasso regression analysis. Internal and external validations were performed and the validity of the model was validated in a real-world cohort. Finally, preliminary experimental verifications were carried out to verify the biological functions of SH2D2A in bladder cancer.

Results

A total of 52 CD8+ T cell-related prognostic genes were screened and two molecular clusters with notably diverse immune cell infiltration, prognosis and clinical features were developed. Then, a novel CD8+ T cell-related prognostic model was constructed. The patients with high-risk scores exhibited a significantly worse overall survival in training, test, whole TCGA and validating cohort. The AUC was 0.766, 0.725, 0.739 and 0.658 in the four cohorts sequentially. Subgroup analysis suggested that the novel prognostic model has a robust clinical application for selecting high-risk patients. Finally, we confirmed that patients in the low-risk group might benefit more from immunotherapy or chemotherapy, and validated the prognostic model in a real-world immunotherapy cohort. Preliminary experiment showed that SH2D2A was capable of attenuating proliferation, migration and invasion of BCa cells.

Conclusions

CD8+ T cell-related molecular clusters were successfully identified. Besides, a novel CD8+ T cell-related prognostic model with an excellent predictive performance in predicting survival rates and immunotherapy efficacy of BCa was developed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Yang X, Ye T, Liu H, Lv P, Duan C, Wu X, Jiang K, Lu H, Xia D, Peng E, Chen Z, Tang K, Ye Z. Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. Mol Cancer. 2021;20:4.CrossRefPubMedPubMedCentral Yang X, Ye T, Liu H, Lv P, Duan C, Wu X, Jiang K, Lu H, Xia D, Peng E, Chen Z, Tang K, Ye Z. Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer. Mol Cancer. 2021;20:4.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Liu Y, Huang W, Cai Z. Synthesizing AND gate minigene circuits based on CRISPReader for identification of bladder cancer cells. Nat Commun. 2020;11:5486.CrossRefPubMedPubMedCentral Liu Y, Huang W, Cai Z. Synthesizing AND gate minigene circuits based on CRISPReader for identification of bladder cancer cells. Nat Commun. 2020;11:5486.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Lu Q, Liu T, Feng H, Yang R, Zhao X, Chen W, Jiang B, Qin H, Guo X, Liu M, Li L, Guo H. Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN. Mol Cancer. 2019;18:111.CrossRefPubMedPubMedCentral Lu Q, Liu T, Feng H, Yang R, Zhao X, Chen W, Jiang B, Qin H, Guo X, Liu M, Li L, Guo H. Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN. Mol Cancer. 2019;18:111.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kita Y, Hamada A, Saito R, Teramoto Y, Tanaka R, Takano K, Nakayama K, Murakami K, Matsumoto K, Akamatsu S, Yamasaki T, Inoue T, Tabata Y, Okuno Y, Ogawa O, Kobayashi T. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. Br J Cancer. 2019;121:1027–38.CrossRefPubMedPubMedCentral Kita Y, Hamada A, Saito R, Teramoto Y, Tanaka R, Takano K, Nakayama K, Murakami K, Matsumoto K, Akamatsu S, Yamasaki T, Inoue T, Tabata Y, Okuno Y, Ogawa O, Kobayashi T. Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. Br J Cancer. 2019;121:1027–38.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Yadollahvandmiandoab R, Jalalizadeh M, Buosi K, Garcia-Perdomo HA, Reis LO. Immunogenic cell death role in urothelial cancer therapy. Curr Oncol (Tor, Ont). 2022;29:6700–13.CrossRef Yadollahvandmiandoab R, Jalalizadeh M, Buosi K, Garcia-Perdomo HA, Reis LO. Immunogenic cell death role in urothelial cancer therapy. Curr Oncol (Tor, Ont). 2022;29:6700–13.CrossRef
6.
Zurück zum Zitat Ren D, Hua Y, Yu B, Ye X, He Z, Li C, Wang J, Mo Y, Wei X, Chen Y, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Zeng Z, Xiong W. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19:19.CrossRefPubMedPubMedCentral Ren D, Hua Y, Yu B, Ye X, He Z, Li C, Wang J, Mo Y, Wei X, Chen Y, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Zeng Z, Xiong W. Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19:19.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Deng C, Xu Y, Fu J, Zhu X, Chen H, Xu H, Wang G, Song Y, Song G, Lu J, Liu R, Tang Q, Huang W, Wang J. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. Cancer Sci. 2020;111:1899–909.CrossRefPubMedPubMedCentral Deng C, Xu Y, Fu J, Zhu X, Chen H, Xu H, Wang G, Song Y, Song G, Lu J, Liu R, Tang Q, Huang W, Wang J. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma. Cancer Sci. 2020;111:1899–909.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Leclerc M, Voilin E, Gros G, Corgnac S, de Montpréville V, Validire P, Bismuth G, Mami-Chouaib F. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345.CrossRefPubMedPubMedCentral Leclerc M, Voilin E, Gros G, Corgnac S, de Montpréville V, Validire P, Bismuth G, Mami-Chouaib F. Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1. Nat Commun. 2019;10:3345.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Liu A, Xia Y, Li W, Zhang G, Liu Y, Ye S, Zhao ZR, Yang Y, Jia Y, Guo Y, Liu X, Chen H, Yu J. The predictive value of changes in the absolute counts of peripheral lymphocyte subsets for progression and prognosis in breast cancer patients. Contrast Media Mol Imaging. 2022;2022:3444360.CrossRefPubMedPubMedCentral Liu A, Xia Y, Li W, Zhang G, Liu Y, Ye S, Zhao ZR, Yang Y, Jia Y, Guo Y, Liu X, Chen H, Yu J. The predictive value of changes in the absolute counts of peripheral lymphocyte subsets for progression and prognosis in breast cancer patients. Contrast Media Mol Imaging. 2022;2022:3444360.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Chabab G, Boissière-Michot F, Mollevi C, Ramos J, Lopez-Crapez E, Colombo PE, Jacot W, Bonnefoy N, Lafont V. Diversity of tumor-infiltrating, γδ T-cell abundance in solid cancers. Cells. 2020;9:1537.CrossRefPubMedPubMedCentral Chabab G, Boissière-Michot F, Mollevi C, Ramos J, Lopez-Crapez E, Colombo PE, Jacot W, Bonnefoy N, Lafont V. Diversity of tumor-infiltrating, γδ T-cell abundance in solid cancers. Cells. 2020;9:1537.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Luo D, Kuang F, Du J, Zhou M, Peng F, Gan Y, Fang C, Yang X, Li B, Su S. Characterization of the immune cell infiltration profile in pancreatic carcinoma to aid in immunotherapy. Front Oncol. 2021;11: 677609.CrossRefPubMedPubMedCentral Luo D, Kuang F, Du J, Zhou M, Peng F, Gan Y, Fang C, Yang X, Li B, Su S. Characterization of the immune cell infiltration profile in pancreatic carcinoma to aid in immunotherapy. Front Oncol. 2021;11: 677609.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Shimizu S, Hiratsuka H, Koike K, Tsuchihashi K, Sonoda T, Ogi K, Miyakawa A, Kobayashi J, Kaneko T, Igarashi T, Hasegawa T, Miyazaki A. Tumor-infiltrating CD8(+) T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 2019;8:80–93.CrossRefPubMedPubMedCentral Shimizu S, Hiratsuka H, Koike K, Tsuchihashi K, Sonoda T, Ogi K, Miyakawa A, Kobayashi J, Kaneko T, Igarashi T, Hasegawa T, Miyazaki A. Tumor-infiltrating CD8(+) T-cell density is an independent prognostic marker for oral squamous cell carcinoma. Cancer Med. 2019;8:80–93.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat He D, Zhang X, Tu J. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma. Cancer Med. 2020;9:8782–800.CrossRefPubMedPubMedCentral He D, Zhang X, Tu J. Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma. Cancer Med. 2020;9:8782–800.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Sun M, Ji X, Xie M, Chen X, Zhang B, Luo X, Feng Y, Liu D, Wang Y, Li Y, Liu B, Xia L, Huang W. Identification of necroptosis-related subtypes, development of a novel signature, and characterization of immune infiltration in colorectal cancer. Front Immunol. 2022;13: 999084.CrossRefPubMedPubMedCentral Sun M, Ji X, Xie M, Chen X, Zhang B, Luo X, Feng Y, Liu D, Wang Y, Li Y, Liu B, Xia L, Huang W. Identification of necroptosis-related subtypes, development of a novel signature, and characterization of immune infiltration in colorectal cancer. Front Immunol. 2022;13: 999084.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Goutas D, Palamaris K, Stofas A, Politakis N, Despotidi A, Giannopoulou I, Goutas N, Vlachodimitropoulos D, Kavantzas N, Lazaris AC, Gakiopoulou H. Immunohistochemical study of bladder cancer molecular subtypes and their association with PD-L1 expression. Cancers. 2022;15:188.CrossRefPubMedPubMedCentral Goutas D, Palamaris K, Stofas A, Politakis N, Despotidi A, Giannopoulou I, Goutas N, Vlachodimitropoulos D, Kavantzas N, Lazaris AC, Gakiopoulou H. Immunohistochemical study of bladder cancer molecular subtypes and their association with PD-L1 expression. Cancers. 2022;15:188.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Voutsadakis IA. Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies. Curr Oncol (Tor, Ont). 2022;29:1390–407.CrossRef Voutsadakis IA. Urothelial bladder carcinomas with high tumor mutation burden have a better prognosis and targetable molecular defects beyond immunotherapies. Curr Oncol (Tor, Ont). 2022;29:1390–407.CrossRef
18.
Zurück zum Zitat Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA. Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells. Mol Cancer Res. 2005;3:21–31.CrossRefPubMed Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA. Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells. Mol Cancer Res. 2005;3:21–31.CrossRefPubMed
19.
Zurück zum Zitat Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun. 2003;304:437–44.CrossRefPubMed Scorrano L, Korsmeyer SJ. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun. 2003;304:437–44.CrossRefPubMed
20.
Zurück zum Zitat Raji GR, Poyyakkara A, Krishnan AK, Maurya AK, Changmai U, Shankar SS, Kumar VBS. Horizontal transfer of miR-643 from cisplatin-resistant cells confers chemoresistance to recipient drug-sensitive cells by targeting APOL6. Cells. 2021;10:1341.CrossRefPubMedPubMedCentral Raji GR, Poyyakkara A, Krishnan AK, Maurya AK, Changmai U, Shankar SS, Kumar VBS. Horizontal transfer of miR-643 from cisplatin-resistant cells confers chemoresistance to recipient drug-sensitive cells by targeting APOL6. Cells. 2021;10:1341.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Liu K, Chen Y, Li B, Li Y, Liang X, Lin H, Luo L, Chen T, Dai Y, Pang W, Zeng L. Upregulation of apolipoprotein L6 improves tumor immunotherapy by inducing immunogenic cell death. Biomolecules. 2023;13:415.CrossRefPubMedPubMedCentral Liu K, Chen Y, Li B, Li Y, Liang X, Lin H, Luo L, Chen T, Dai Y, Pang W, Zeng L. Upregulation of apolipoprotein L6 improves tumor immunotherapy by inducing immunogenic cell death. Biomolecules. 2023;13:415.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377–81.CrossRefPubMedPubMedCentral Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377–81.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, Telenius A, Chavez E, Ramchandani S, Drake M, Boyle M, Ben-Neriah S, Scott DW, Rimsza LM, Siebert R, Gascoyne RD, Steidl C. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 2015;13:1418–31.CrossRefPubMed Mottok A, Woolcock B, Chan FC, Tong KM, Chong L, Farinha P, Telenius A, Chavez E, Ramchandani S, Drake M, Boyle M, Ben-Neriah S, Scott DW, Rimsza LM, Siebert R, Gascoyne RD, Steidl C. Genomic alterations in CIITA are frequent in primary mediastinal large B cell lymphoma and are associated with diminished MHC class II expression. Cell Rep. 2015;13:1418–31.CrossRefPubMed
24.
Zurück zum Zitat Neuwelt AJ, Kimball AK, Johnson AM, Arnold BW, Bullock BL, Kaspar RE, Kleczko EK, Kwak JW, Wu MH, Heasley LE, Doebele RC, Li HY, Nemenoff RA, Clambey ET. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. J Immunother Cancer. 2020;8:e000441.CrossRefPubMedPubMedCentral Neuwelt AJ, Kimball AK, Johnson AM, Arnold BW, Bullock BL, Kaspar RE, Kleczko EK, Kwak JW, Wu MH, Heasley LE, Doebele RC, Li HY, Nemenoff RA, Clambey ET. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. J Immunother Cancer. 2020;8:e000441.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Redelman-Sidi G, Binyamin A, Antonelli AC, Catalano W, Bean J, Al-Ahmadie H, Jungbluth AA, Glickman MS. BCG-induced tumor immunity requires tumor-intrinsic CIITA independent of MHC-II. Cancer Immunol Res. 2022;10:1241–53.CrossRefPubMedPubMedCentral Redelman-Sidi G, Binyamin A, Antonelli AC, Catalano W, Bean J, Al-Ahmadie H, Jungbluth AA, Glickman MS. BCG-induced tumor immunity requires tumor-intrinsic CIITA independent of MHC-II. Cancer Immunol Res. 2022;10:1241–53.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Pezzè L, Meškytė EM, Forcato M, Pontalti S, Badowska KA, Rizzotto D, Skvortsova II, Bicciato S, Ciribilli Y II. ETV7 regulates breast cancer stem-like cell features by repressing IFN-response genes. Cell Death Dis. 2021;12:742.CrossRefPubMedPubMedCentral Pezzè L, Meškytė EM, Forcato M, Pontalti S, Badowska KA, Rizzotto D, Skvortsova II, Bicciato S, Ciribilli Y II. ETV7 regulates breast cancer stem-like cell features by repressing IFN-response genes. Cell Death Dis. 2021;12:742.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Qu H, Zhao H, Zhang X, Liu Y, Li F, Sun L, Song Z. Integrated analysis of the ETS family in melanoma reveals a regulatory role of ETV7 in the immune microenvironment. Front Immunol. 2020;11: 612784.CrossRefPubMedPubMedCentral Qu H, Zhao H, Zhang X, Liu Y, Li F, Sun L, Song Z. Integrated analysis of the ETS family in melanoma reveals a regulatory role of ETV7 in the immune microenvironment. Front Immunol. 2020;11: 612784.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Harwood FC, Klein Geltink RI, O’Hara BP, Cardone M, Janke L, Finkelstein D, Entin I, Paul L, Houghton PJ, Grosveld GC. ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Sci Adv. 2018;4:3938.CrossRef Harwood FC, Klein Geltink RI, O’Hara BP, Cardone M, Janke L, Finkelstein D, Entin I, Paul L, Houghton PJ, Grosveld GC. ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer. Sci Adv. 2018;4:3938.CrossRef
29.
Zurück zum Zitat Sang Y, Cheng C, Zeng YX, Kang T. Snail promotes metastasis of nasopharyngeal carcinoma partly by down-regulating TEL2. Cancer Commun (Lond, Engl). 2018;38:58. Sang Y, Cheng C, Zeng YX, Kang T. Snail promotes metastasis of nasopharyngeal carcinoma partly by down-regulating TEL2. Cancer Commun (Lond, Engl). 2018;38:58.
30.
Zurück zum Zitat Li H, Zhang Y, Zheng S. Comprehensive analysis identified ETV7 as a potential prognostic biomarker in bladder cancer. Biomed Res Int. 2021;2021:8530186.CrossRefPubMedPubMedCentral Li H, Zhang Y, Zheng S. Comprehensive analysis identified ETV7 as a potential prognostic biomarker in bladder cancer. Biomed Res Int. 2021;2021:8530186.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Wedel J, Stack MP, Seto T, Sheehan MM, Flynn EA, Stillman IE, Kong SW, Liu K, Briscoe DM. T cell-specific adaptor protein regulates mitochondrial function and CD4(+) T regulatory cell activity in vivo following transplantation. J Immuno (Baltimore, MD). 1950;203(2019):2328–38. Wedel J, Stack MP, Seto T, Sheehan MM, Flynn EA, Stillman IE, Kong SW, Liu K, Briscoe DM. T cell-specific adaptor protein regulates mitochondrial function and CD4(+) T regulatory cell activity in vivo following transplantation. J Immuno (Baltimore, MD). 1950;203(2019):2328–38.
32.
Zurück zum Zitat Abrahamsen G, Sundvold-Gjerstad V, Habtamu M, Bogen B, Spurkland A. Polarity of CD4+ T cells towards the antigen presenting cell is regulated by the Lck adapter TSAd. Sci Rep. 2018;8:13319.CrossRefPubMedPubMedCentral Abrahamsen G, Sundvold-Gjerstad V, Habtamu M, Bogen B, Spurkland A. Polarity of CD4+ T cells towards the antigen presenting cell is regulated by the Lck adapter TSAd. Sci Rep. 2018;8:13319.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Berge T, Grønningsæter IH, Lorvik KB, Abrahamsen G, Granum S, Sundvold-Gjerstad V, Corthay A, Bogen B, Spurkland A. SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS ONE. 2012;7: e48239.CrossRefPubMedPubMedCentral Berge T, Grønningsæter IH, Lorvik KB, Abrahamsen G, Granum S, Sundvold-Gjerstad V, Corthay A, Bogen B, Spurkland A. SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS ONE. 2012;7: e48239.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Shi Y, Zhang D, Chen J, Jiang Q, Song S, Mi Y, Wang T, Ye Q. Interaction between BEND5 and RBPJ suppresses breast cancer growth and metastasis via inhibiting Notch signaling. Int J Biol Sci. 2022;18:4233–44.CrossRefPubMedPubMedCentral Shi Y, Zhang D, Chen J, Jiang Q, Song S, Mi Y, Wang T, Ye Q. Interaction between BEND5 and RBPJ suppresses breast cancer growth and metastasis via inhibiting Notch signaling. Int J Biol Sci. 2022;18:4233–44.CrossRefPubMedPubMedCentral
35.
36.
Zurück zum Zitat Liu J, Tan Z, He J, Jin T, Han Y, Hu L, Song J, Huang S. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value. Biosci Rep. 2020;40:BSR20201431.CrossRefPubMedPubMedCentral Liu J, Tan Z, He J, Jin T, Han Y, Hu L, Song J, Huang S. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value. Biosci Rep. 2020;40:BSR20201431.CrossRefPubMedPubMedCentral
37.
39.
Zurück zum Zitat Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633–41.CrossRefPubMedPubMedCentral Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N, Hollmann T, Schalper KA, Gainor JF, Shen R, Ni A, Arbour KC, Merghoub T, Wolchok J, Snyder A, Chaft JE, Kris MG, Rudin CM, Socci ND, Berger MF, Taylor BS, Zehir A, Solit DB, Arcila ME, Ladanyi M, Riely GJ, Schultz N, Hellmann MD. Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633–41.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Xie M, Chen D, Li Y, Liu X, Kuang D, Li X. Genetic mutation profiles and immune microenvironment analysis of pulmonary enteric adenocarcinoma. Diagn Pathol. 2022;17:30.CrossRefPubMedPubMedCentral Xie M, Chen D, Li Y, Liu X, Kuang D, Li X. Genetic mutation profiles and immune microenvironment analysis of pulmonary enteric adenocarcinoma. Diagn Pathol. 2022;17:30.CrossRefPubMedPubMedCentral
Metadaten
Titel
A novel CD8+ T cell-related gene signature for predicting the prognosis and immunotherapy efficacy in bladder cancer
verfasst von
Fei Lin
Zhi-Bin Ke
Yu-Ting Xue
Jia-Yin Chen
Hai Cai
Yun-Zhi Lin
Xiao-Dong Li
Yong Wei
Xue-Yi Xue
Ning Xu
Publikationsdatum
14.08.2023
Verlag
Springer International Publishing
Erschienen in
Inflammation Research / Ausgabe 8/2023
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-023-01772-6

Weitere Artikel der Ausgabe 8/2023

Inflammation Research 8/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.